The fluoroquinolones are exceptionally potent antibacterial agents that are widely used for the treatment of a wide variety of infections (14, 15, 29, 30) . Fluoroquinolones interact with two related but distinct targets within the bacterial cell, DNA gyrase and DNA topoisomerase IV (22, 32) . Both are type II topoisomerases, enzymes required for DNA metabolism that introduce transient double-stranded breaks in DNA and that then pass another duplex segment of DNA through the break and religate the broken ends (for reviews, see references 7, 11, 42, 46, 55, and 56) .
DNA gyrase is unique among the type II enzymes, in that it can introduce negative superhelical turns into DNA (12, 22, 47) . Topoisomerase IV but not DNA gyrase unlinks catenated intermediates of replicated and recombined DNA molecules, as well as unknots DNA (12, 61, 62) . Fluoroquinolones interfere with the topoisomerase reaction by disrupting the DNA breakage-reunion reaction, resulting in the trapping of both DNA gyrase and topoisomerase IV at a point in the reaction cycle where the enzyme is covalently bound to DNA (21, 33) . Although both enzymes carry out indispensable reactions, trapping of the covalent complex and the generation of enzyme-mediated DNA damage causes cell killing (34, 39) .
The majority of known cases of quinolone resistance encountered in clinical isolates, as well as the majority of cases of laboratory selection of mutations, results from mutations in chromosomal genes that lead to alterations in the drug targets (1, 10, 15, 27, 38, 49, 50) . Mutations in GyrA, the gene for which (gyrA) encodes the A subunit of DNA gyrase, are the most common mechanisms involved in quinolone resistance among gram-negative bacteria. Moreover, mutations in parC (grlA in Staphylococcus aureus), the gene encoding the homologous A subunit of topoisomerase IV, are most commonly encountered among quinolone-resistant gram-positive bacteria (1, 14, 15, 27, 50) . Mutations within the genes encoding GyrA and ParC occur within conserved regions (15, 50) . These hot spots for quinolone resistance have been termed quinolone resistance-determining regions and are located between amino acids 67 and 106 in GyrA, with amino acids 83 and 87 most often being involved (15, 26, 50, 57, 59) . Similar hot spots were found in analogous regions of ParC (19, 20, 25, 34, 41) . Mutations that change Ser 83 to either leucine or tryptophan confer high levels of quinolone resistance (ϳ10-fold increase), whereas mutations that change Ser 83 to alanine result in lower levels of quinolone resistance (ϳ5-fold increase) (9) .
Previous studies (31, 53) (16) . In addition to quinolone resistance, the Ser 740 Trp mutation also rendered yeast topoisomerase II hypersensitive to etoposide (31, 53) . The demethylepipodophyllotoxins etoposide (VP-16) and teniposide (VM-26) are nonintercalating drugs that inhibit eukaryotic type II topoisomerases by increasing the levels of DNA cleavage complexes primarily by impairing the ability of the enzyme to religate the cleaved DNA (4, 35, 36, 46) . The mechanism of eukaryotic cell killing by these agents is similar to that described above for the actions of fluoroquinolones against bacteria, i.e., the generation of enzyme-mediated DNA damage. Most of the drugs, like etoposide, that act against eukaryotic topoisomerase II do not have activity against bacterial cells and have only limited activity against the purified prokaryotic enzymes (6) . Because bacterial cells have efficient efflux pumps that contribute to both intrinsic and acquired resistance to inhibitors of prokaryotic type II topoisomerases (8, 44, 48, 58) , investigation of the effects of epipodophyllotoxins on viable cells requires the inactivation of efflux pump activity. This can be achieved by either loss-of-function mutations or inhibition of the pumps with efflux pump inhibitors such as MC-207,110 (37) .
This study demonstrates that a single point mutation, Ser 83 Trp, in the gyrase-encoding gene, gyrA, is associated with high-level quinolone resistance and causes enzyme and bacterial sensitivity to other antitopoisomerase drug classes, like demethylepipodophyllotoxins and amino-azatoxin [11␤-(2Љ-N,N-dimethylaminoethyl)-amino-azatoxin], for which wildtype gyrase is refractory. Our results suggest a novel strategy of drug screening to take into account the fact that certain drugs might be active against quinolone-resistant DNA gyrases, even though the wild-type gyrase is insensitive.
MATERIALS AND METHODS
Antibiotics, enzymes, and growth medium. Cation-adjusted Mueller-Hinton broth was from Difco (Detroit, Mich.). Standard broth no. 1 (NI agar and NI broth) was from Merck (Darmstadt, Germany). Ciprofloxacin was from Bayer AG (Wuppertal, Germany); chloramphenicol was from by Boehringer Mannheim (Mannheim, Germany); MC-207,110, Phe-Arg-␤-naphthylamide, was from Sigma (Munich, Germany); and etoposide (VP-16) was from Bristol Arzneimittel GmbH (Munich, Germany). Amino-azatoxin was kindly provided by T. Macdonald, Department of Chemistry, University of Virginia, Charlottesville. All drug stock solutions were prepared in dimethyl sulfoxide at 10 mM. Further dilutions were made in distilled water immediately before use. Expand HighFidelity polymerase (Roche, Mannheim, Germany) was used for PCR. BamHI restriction endonuclease was purchased from Life Technologies (Eggenstein, Germany). Human c-myc inserted into pBR322, T4 polynucleotide kinase, and polyacrylamide and bisacrylamide were purchased from Lofstrand Labs (Gaithersburg, Md. (28) . The plasmids used were pMAK705 (23), pMAK705-242 (this study), pBR322 from strain C600 (laboratory stock), and pBR322-242 (this study).
Site-directed mutagenesis of gyrA in E. coli. The allelic exchange technique (23) was applied to introduce into the chromosomal gyrA gene the S83W point mutation associated with quinolone resistance. Briefly, a PCR fragment from strain 4917 carrying the mutation flanked by BamHI restriction sites was first cloned into pBR322 to give pBR322-242. The gyrA BamHI fragment was isolated from pBR322-242 and subcloned into the BamHI site within the polylinker region of pMAK705 to give pMAK705-242 (Fig. 1) . This plasmid was transformed into strain RFM443 by electroporation with a Gene Pulser apparatus (Bio-Rad, Munich, Germany). The presence of the gyrA S83W mutation in pBR322-242, pMAK705-242, and strain RFM443-242 was verified by DNA sequencing.
Drug susceptibility assay. MICs were determined by a twofold microdilution method with cation-adjusted Mueller-Hinton broth, in accordance with the recommendations of NCCLS (40) . The final inoculum of 5 ϫ 10 5 to 1 ϫ 10 6 CFU/ml (verified by plating) was prepared by diluting suspensions harvested from overnight cultures from Luria-Bertani agar plates. The trays were incubated at 37°C for 20 h.
Time course of drug susceptibility. Flasks (100 ml) containing 10 ml of standard broth no. 1 were inoculated with exponentially growing cells and were incubated for an additional 2 h at 37°C in a rotating shaker (200 rpm) to reach a cell density of approximately 10 6 CFU/ml. Drugs were then added to the culture, and 0.5-ml aliquots were taken at various times to determine the number of viable cells.
DNA supercoiling reactions. Relaxed substrate DNA was prepared by incubating native simian virus 40 (SV40) DNA with topoisomerase I (calf thymus; GIBCO/BRL) for 2 h at 37°C. DNA supercoiling reactions were carried out in a total reaction volume of 20 l containing 30 mM Tris-HCl (pH 7.5), 25 mM KCl, 4 mM MgCl 2 , 5 mM dithiothreitol, 30 g of bovine serum albumin/ml, 9 g of tRNA/ml, 2 mM spermidine, 1.5 mM ATP, 375 ng of relaxed SV40 DNA, and 140 ng of DNA gyrase. The reaction mixtures were incubated at 37°C for 30 min, and the reactions were stopped by the addition of 20 l of chloroform. Samples were separated on 0.8% agarose gels. Gels were stained with ethidium bromide and viewed under UV light (300 nm). Quantitation of the amount of supercoiled DNA was performed with ImageQuant software. The amount of supercoiled DNA generated by gyrase with or without additional drug was calculated as a percentage of the total SV40 DNA (including nicked DNA, the various forms of remaining relaxed DNA, and supercoiled DNA), which was separated on agarose gels.
Preparation of end-labeled DNA fragments by PCR. Three sets of labeled DNA fragments were prepared from the human c-myc gene by PCR: a 254-bp DNA fragment from the first intron between nucleotides (nt) 3035 and 3288 (GenBank accession no. X00364) was prepared with oligonucleotide 5Ј-GTAA TCCAGAACTGGATCGG-3Ј for the upper (coding) strand and oligonucleotide 5Ј-ATGCGGTCCCTACTCCAAGG-3Ј for the lower (noncoding or antisense) strand (annealing temperature, 56°C). A 401-bp DNA fragment from the junction between the first intron and the first exon (between nt 2671 and 3072) was prepared with oligonucleotide 5Ј-TGCCGCATCCACGAAACTTT-3Ј for the upper (coding) strand and oligonucleotide 5Ј-TTGACAAGTCACTTTACCC C-3Ј for the lower (noncoding or antisense) strand (annealing temperature, 60°C). A 480-bp fragment from the first exon containing promoters P 1 and P 2 (between nt 2265 and 2745) was prepared with oligonucleotide 5Ј-GATCCTCT CTCGCTAATCTCCGCCC-3Ј for the upper (coding) strand and oligonucleotide 5Ј-TCCTTGCTCGGGTGTTGTAAGTTCC-3Ј for the lower (noncoding or antisense) strand (annealing temperature, 70°C). A 213-bp fragment from the human c-jun gene (51) was prepared with primer 5Ј-TGTTGACAGCGGCGG AAAGCAGS-3Ј for the upper (coding) strand and primer 5Ј-CGTCCTTCTTC TCTTGCGTGGCTCT-3Ј for the lower (noncoding or antisense) strand (annealing temperature, 64°C). Single-end labeling of these DNA fragments was achieved by 5Ј end labeling of the specific primer oligonucleotide (53) , and the labeled oligonucleotides were used thereafter for PCR. Approximately 0.1 g of the c-myc DNA that had been restricted with SmaI and PvuII (the fragment from positions 2265 to 2745) and with XhoI and XbaI (the fragments from positions 2671 to 3072 and positions 3035 to 3288, respectively) was used as the template for the PCR. Ten picomoles of each oligonucleotide primer, one of which was 5Ј labeled, was used in 22 temperature cycle reactions (with each cycle consisting of 94°C for 1 min, annealing for 1 min, and 72°C for 2 min).
Mapping and base sequence analysis of drug-induced DNA cleavage. DNA fragments (5 ϫ 10 4 to 8 ϫ 10 4 dpm/reaction mixture) were equilibrated in cleavage buffer (10 mM Tris-HCl [pH 7.5], 50 mM KCl, 5 mM MgCl 2 , 2 mM dithiothreitol, 0.1 mM disodium EDTA, 1 mM ATP, 15 g of bovine serum albumin/ml) and drug or a 1% dimethyl sulfoxide blank was added. After 5 min of incubation, 70 ng of purified E. coli gyrase was added to give a final reaction volume of 10 l. The reaction mixtures were incubated for 120 min at 25°C and stopped by adding EDTA and sodium dodecyl sulfate (final concentrations, 25 mM and 1%, respectively) and were further digested with proteinase K. For DNA sequence analysis, samples were separated on denaturing DNA sequencing gels and were thereafter visualized with a PhosphorImager (Molecular Dynamics, Sunnyvale, Calif.) and ImageQuant software. The preferred bases around the gyrase DNA cleavage sites were identified as described previously (5, 45, 54) .
Quantitation of drug-induced DNA cleavage. The reaction mixtures used to quantitate drug-induced DNA cleavage included 140 ng of enzyme and 250 ng of negatively supercoiled SV40 DNA (GIBCO/BRL) in a total of 10 l of cleavage buffer (the same buffer used for drug-induced DNA fragment cleavage). The reaction mixtures were incubated for 120 min at 25°C and stopped by adding EDTA and sodium dodecyl sulfate (final concentrations, 25 mM and 1%, respectively), and they were further digested with proteinase K. DNA fragments were separated on 0.8% agarose gels and were visualized after electrophoresis (in Tris-borate-EDTA containing 0.05 g of ethidium bromide/ml) by UV transillumination (300 nm). The amount of linearized DNA (i.e., DNA with doublestranded breaks) was quantitated with ImageQuant and Microsoft Excel software.
RESULTS
Our first experiments tested whether the Ser 83 3Trp mutation in DNA gyrase changed the catalytic activity of the mutant enzyme in the presence of agents active against the eukaryotic enzyme. We analyzed the effect of epipodophyllotoxins and amino-azatoxin on wild-type DNA gyrase (Gyr WT )-and GyrA S83W -catalyzed supercoiling of relaxed SV40 DNA (Fig.  2) . In the absence of drugs, both enzymes supercoiled relaxed SV40 DNA without detectable differences in efficacy. In the presence of ciprofloxacin ( Fig. 2A) , Gyr WT showed complete inhibition of supercoiling at 3 M, whereas, as expected, the mutant GyrA S83W protein retained supercoiling activity in the presence of 100 M ciprofloxacin. We observed a different pattern of inhibition in the presence of etoposide (Fig. 2B) . The Gyr WT protein showed undiminished supercoiling activity in the presence of etoposide at a concentration of 100 M, and the mutant GyrA S83W enzyme displayed reduced supercoiling activity in the presence of 3 M etoposide and nearly complete inhibition in the presence of 100 M etoposide. We observed similar patterns of inhibition of supercoiling with teniposide and amino-azatoxin (Fig. 2C) .
Enhanced DNA cleavage by epipodophyllotoxins (etoposide and teniposide) and amino-azatoxin with the Ser 83 Trp mutant gyrase. We measured DNA cleavage by purified E. coli Gyr WT or GyrA S83W in the presence of either the fluoroquinolone ciprofloxacin or the epipodophyllotoxins etoposide and teniposide or amino-azatoxin (Fig. 3) . The gyrase-induced DNA double-stranded breaks were measured and are illustrated in Fig. 3A for ciprofloxacin and Fig. 3B for etoposide. The levels of linearized DNA were quantitated; and plots of the levels of linearized DNA in the presence of ciprofloxacin, etoposide, teniposide, and amino-azatoxin are shown in Fig. 3C . In the absence of drug, both Gyr WT and GyrA S83W enzymes generated low levels of linearized DNA. In the presence of ciprofloxacin at concentrations ranging from 3 to 100 M, approximately 40% linearized DNA was reached with Gyr WT . DNA cleavage was markedly reduced with the mutant GyrA S83W in the presence of ciprofloxacin, even at concentrations greater than 100 M. Importantly, the opposite result was seen with etoposide, teniposide, and amino-azatoxin ( Fig. 3B and C) . The generation of linearized DNA by Gyr WT was not significantly stimulated by etoposide, teniposide, or amino-azatoxin. In contrast, the mutant GyrA S83W protein showed at least twofold larger amounts of linearized DNA in the presence of etoposide, teniposide, or amino-azatoxin. Different DNA cleavage sites for GyrA S83W compared to those for Gyr WT in the presence of etoposide and amino-azatoxin. To investigate the basis for the enhanced DNA cleavage activity of GyrA S83W in the presence of specific drugs, we mapped the DNA cleavage sites induced by mutant GyrA S83W and Gyr WT in the presence of etoposide and amino-azatoxin (Fig. 4) . Even in the absence of drugs, differences in the cleavage sites induced by mutant GyrA S83W and Gyr WT could be observed. The GyrA S83W mutant protein caused increased We next asked whether enhanced DNA cleavage activity and alterations in cleavage patterns were associated with an altered sequence specificity of GyrA S83W in the presence of these drugs ( Fig. 5 Table 1 ). This result correlates well with previous DNA cleavage analyses of eukaryotic topoisomerase II proteins in the presence of etoposide (4, 46, 51) . Taken together, the data indicate that changes in the protein-drug interaction resulting from the Ser 83 3Trp mutation in gyrase enhance DNA cleavage activity in the presence of etoposide. However, enhanced DNA cleavage activity with the GyrA S83W protein in the presence of drugs was not associated with increased stability (i.e., stability in the presence of heat and salt) of the covalent complexes (data not shown).
Susceptibilities of quinolone-sensible and -resistant E. coli strains. Our next goal was to demonstrate that etoposide could Pilot experiments failed to demonstrate etoposide sensitivity in a variety of different strains. Since etoposide was unlikely to accumulate to significant levels in wild-type E. coli cells, we needed to be able to increase the drug levels by either increasing influx or decreasing efflux. We chose to use a chemical inhibitor of drug efflux. AcrAB is a drug efflux protein that can be inhibited by MC-207,110 (37). Therefore, we treated E. coli strain RFM443 and a GyrA S83W derivative (RFM443-242) with 40 M MC-207,110 in the presence or absence of anticancer drugs targeting topoisomerase II (Fig. 6) . Inhibition of drug efflux by MC-207,110 (final concentration, 40 M) did not affect the ciprofloxacin sensitivity of wild-type strain RFM443 or mutant strain RFM443-242 (Fig.  6A ). This result is consistent with the view that ciprofloxacin resistance in strain RFM443-242 is solely due to the Ser . Similar results were obtained with amino-azatoxin (Fig. 6C) and teniposide (data not shown) . This experiment shows that etoposide and other topoisomerase II poisons can kill E. coli cells, provided that the cells carry a sensitizing mutation and a condition that can lead to enhanced drug accumulation. Taken together, our results show that etoposide, teniposide, and amino-azatoxin are active against E. coli GyrA S83W .
DISCUSSION
In previous studies, we analyzed several point mutations within the ␣4 helix of the CAP homology domain of eukaryotic (yeast) type II topoisomerases (13, 31, 53) . Since we observed mutations in the eukaryotic enzyme that could enhance sensitivity to some classes of inhibitors, we reasoned that homologous mutations could be used to assess whether prokaryotic topoisomerase II could be inhibited by agents thought to be specific for the eukaryotic enzyme. We carried out the analysis at the biochemical level, using purified DNA gyrase, and assessed the sensitivities of E. coli cells carrying an appropriate gyrase mutation. Our results clearly demonstrate that the Ser 83 change in GyrA results in an enzyme that is sensitive to etoposide and related topoisomerase II inhibitors, whereas the wild-type enzyme is relatively insensitive to these agents.
Interestingly, the mutant with the Ser 83 -to-Trp mutation shares biochemical properties with the eukaryotic enzymes mutated at homologous positions. Previous studies showed that this mutant enzyme had alterations in DNA cleavage specificity even in the absence of drug (52) . Etoposide-induced cleavage sites for gyrase carrying GyrA S83W showed the same preference for C at position Ϫ1 described for the wild-type yeast and human enzymes (3, 45) . Not surprisingly, the properties of the prokaryotic enzyme do not exactly mimic all of those of the eukaryotic mutant enzyme. For example, the FIG. 5. Probability of the observed deviations in base frequency at DNA cleavage sites for GyrA S83W in the presence of etoposide. Both DNA strands of three c-myc DNA fragments were analyzed for cleavage sites (see Materials and Methods). Position 0 corresponds to the cleavage site. The probability of the observed base frequency deviations from expectation is shown. On the y axis, P is the probability of observing the indicated deviation more (above the baseline) or less (below the baseline) often relative to the expected frequency of each individual base (45, 51) . Cleavage sites were analyzed after treatment with 100 M etoposide. Ϫ10  Ϫ9  Ϫ8  Ϫ7  Ϫ6  Ϫ5  Ϫ4  Ϫ3  Ϫ2  Ϫ1  1  2  3  4  5  6  7  8  9  1 0   A  30  31  21  25  18  23  34  24  19  16  26  20  22  24  13  27  36  19  20  23  C  29  22  19  18  32  33  14  18  30  48  20  30  28  26  27  15  33  37  23  24  G  18  19  32  27  28  17  22  29  14  11  30  24  22  20  34  24  10  11  29  28  T  14  19  19  21  13  18  21  20  28  16  15  17  19  21  17  25  12  24  19  16 a A total of 91 sites were tested. b Underlined numbers represent base frequencies significantly (P Ͻ 0.001) greater or lower than expected.
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GyrA S83W protein did not demonstrate alterations in base preference, such as C at position Ϫ2 and G at position ϩ6, which were observed for the Saccharomyces Top2p S740W and the human Top2p␣ S763W enzymes (53) . The etoposide-induced cleavage complexes for the GyrA S83W mutant protein did not show heat or salt stability (data not shown), although these were observed with the yeast and human mutant proteins (31, 51) . Nonetheless, we can clearly conclude that DNA gyrase preserves most of the determinants that are required for inhibition by etoposide and related compounds.
There are several important implications for the conservation of most determinants of drug sensitivity between prokaryotic and eukaryotic enzymes. First, drugs targeting topoisomerase II likely bind to regions of the proteins that are very highly conserved between prokaryotic and eukaryotic enzymes. This is not a surprising conclusion, given the high degree of homology found throughout many of the type II topoisomerases (56) . However, the previous assumption that drugs such as etoposide acted against the eukaryotic enzyme but not the prokaryotic enzyme allowed for the possibility that such drugs interact with residues that are not highly conserved between the two kingdoms. Our results argue against this possibility.
Second, our results support the hypothesis that many topoisomerase II-targeting drugs that lead to elevated levels of covalent complexes act near the same site. The existence of mutants leading to quinolone resistance and concomitant etoposide sensitivity suggests that both drugs disrupt the same processes by a change at a particular site on the protein. This conclusion is consistent with the conclusions of previous drug competition studies performed by Osheroff and colleagues (17) , who showed that quinolones inactive against the wildtype eukaryotic enzyme could block the actions of other active inhibitors.
Our studies have concentrated on sites within the gyrA homology domain that can lead to quinolone resistance. Previous work (18, 24, 26, 60) has shown that there are also important determinants of quinolone sensitivity within the gyrB domains of gyrase. Since mutations within the gyrB homology domain of 
